anti-IP6K2 antibody product blog
Tags: Antibody; Monoclonal Antibody; IP6K2; anti-IP6K2 antibody;
The IP6K2 n/a (Catalog #MBS190567) is an Antibody produced from Mouse and is intended for research purposes only. The product is available for immediate purchase. The Anti-Inositol hexakisphosphate kinase 2 (IP6K2) Monoclonal Antibody reacts with Human and may cross-react with other species as described in the data sheet. MyBioSource\'s IP6K2 can be used in a range of immunoassay formats including, but not limited to, Immunoblot.Immunoblotting: A band of ~49 kDa is detected. User should determine optimal concentrations for their application. Positive control: purified human IP6K2 or NIH-OVCAR-3 cells after treatment with interferon (IFN)-beta. Researchers should empirically determine the suitability of the IP6K2 n/a for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
Please refer to the product datasheet for known applications of a given antibody. We\'ve tested the Anti-Inositol hexakisphosphate kinase 2 (IP6K2) Monoclonal Antibody with the following immunoassay(s):
Testing Data
Inositol hexakisphosphate kinase 2 (IP6K2) catalyzes the production of diphosphoinositol pentakisphosphate (IP7) and has a role as a proapoptotic gene sensitizing cancer cells to apoptosis by cell stressors and anticancer drugs all of which depend on IP6K2 catalytic activity. IP6K2 is located in the 3p21.31 chromosomal region, which often undergoes allele loss in a variety of human cancers. Some heat shock proteins, especially Hsp90, can be antiapoptotic and the targets of anticancer drugs. Hsp90 binds IP6K2 and inhibits its catalytic activity. Drugs and selective mutations that abolish HSP90-IP6K2 binding elicit activation of IP6K2, leading to cell death. Thus, the prosurvival actions of HSP90 reflect the inhibition of IP6K2, suggesting that selectively blocking this interaction could provide effective and safer modes of chemotherapy.
Antigen: Full-length recombinant human IP6K2
Preservative: None. Dilution Instructions: Dilute in PBS or medium which is identical to that used in the assay system. In general, we may offer more than one antibody to a given target to enable options for the researcher. Available antibodies recognizing IP6K2 are readily searchable from our website. Different antibodies against the same target such as IP6K2 may be optimized or tested for different applications and species. This enables researchers to select the option that may be best for their model system, to screen more than antibody to determine which one may be best for their model system, as well as to use more than one antibody to follow up on and validate their results.